• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies announces a capital increase of approximately €12.5 million reserved for two investors

Mauna Kea Technologies announces a capital increase of approximately €12.5 million reserved for two investors

by Zina | Sep 20, 2021 | News

This transaction by issuance of Units allows the Company to secure its financing until the end of the third quarter of 2022 Mauna Kea Technologies, inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE and...
Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

by Zina | Aug 24, 2021 | News

The next-generation Cellvizio® platform is now cleared for use with fluorescein dye to image blood flow in the microvasculature and capillaries as a combination drug-device  Mauna Kea Technologies today announces that it has received U.S. Food and Drug...
Mauna Kea Technologies announces a capital increase of approximately €12.5 million reserved for two investors

Mauna Kea Technologies Reports Second Quarter and First Half of 2021 Sales

by Zina | Jul 22, 2021 | News

Mauna Kea Technologies today announced second quarter and first half 2021 sales results for the three and six-month periods ended June 30, 2021.   Second Quarter 2021 Sales Summary:  Total sales for the second quarter of 2021 increased €1.1...

North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)

by Zina | Jul 21, 2021 | Events

The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2021 Conference will be virtual this year over the week of December 12-18, 2021.  Come visit the Cellvizio virtual exhibit!  To learn more on the...
4th Annual Interventional Pulmonology and Advanced Diagnostics Conference – Hybrid

4th Annual Interventional Pulmonology and Advanced Diagnostics Conference – Hybrid

by Zina | Jul 21, 2021 | Events

The American Association for Bronchology and Interventional Pulmonology (AABIP) 2021 Annual Conference will be taking place on August 26 to 28. This year the scientific program will intertwine both digital and physical aspects of the meeting. Come visit the...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}